Search Results - therapeutics+%3e+oncology

120 Results Sort By:
Inhibitors of the N-terminal Domain of the Androgen Receptor (UCLA Case No. 2023-075)
Researchers at UCLA under the guidance of Drs. Matthew Rettig and Michael Jung have developed novel molecular compounds that reduce growth of prostate cancer cells. Dr. Jung in collaboration with Dr. Rettig have furthered the development of these compounds by synthesizing a new series of analogues that have similar inhibitory effects. BACKGROUND: Prostate...
Published: 9/23/2024   |   Inventor(s): Matthew Rettig, Michael Jung
Keywords(s): androgen receptor therapy, castration resistant prostate cancer, Oncology, Oncology (Small Molecules, Peptides and Antibodies), prostate cancer, small molecules
Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)
Compounds and Methods for Treating Cancer by Destroying Cancer Stem Cells (UCLA Case No. 2021-286)
Researchers from UCLA’s Department of Chemistry and Biochemistry and the Department of Radiation Oncology have synthesized a set of compounds for the eradication of cancer stem cells. These compounds are predicted to cross the blood brain barrier and show promise as effective interventions for glioblastoma in both in vitro and in vivo assays. BACKGROUND:...
Published: 7/11/2024   |   Inventor(s): Michael Jung, Frank Pajonk
Keywords(s): blood-brain barrier, Brain, Cancer, Cancer stem cells, drug screening, GBM, Glioblastoma, Glioma, new chemical entity
Category(s): Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Stem Cells And Regenerative Medicine
Methods and Compositions for Treating Melanoma (UCLA Case No. 2021-324)
The Graeber Laboratory at UCLA discovered a novel mechanism for treating melanoma using ferroptosis, a type of programmed cell death, that shows promise against therapy resistance. BACKGROUND: Melanoma is a highly aggressive skin cancer that spreads throughout the body and can be fatal if left untreated. Therapies for melanoma range from immunotherapy...
Published: 7/10/2024   |   Inventor(s): Thomas Graeber
Keywords(s): Cancer, ferroptosis, Immunotherapy, MAPK signaling, Melanoma, Oncology, Skin, tumor resistance
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Multi-Phasic Therapeutic Delivery System (UCLA Case No. 2020-396)
Researchers in the Department of Radiological Sciences at UCLA have conceived a new methodology to overcome obstacles arising after the treatment of tumors by accessing their vascular supply by 1) targeting tumor vessels 2) delivering antineoplastic agents (e.g., chemotherapy or immunotherapy) and 3) delivering anti-angiogenic therapy to reduce blood...
Published: 7/10/2024   |   Inventor(s): Antoinette Gomes
Keywords(s): Anti-Angiogenics, Multiphasic and Multitemporal, Oncology, Therapeutics, Vascular therapy
Category(s): Therapeutics > Oncology, Medical Devices
Engineered T Cells Capable of Simultaneous Tumor Targeting and Alteration of Tumor Microenvironment Through Vasculature Normalization (UCLA Case No. 2023-264)
UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have built a series of chimeric antigen receptor (CAR)-T cells that target different antigens and secrete different anti-angiogenic proteins. Additionally, researchers also constructed bispecific CARs that respond to tumor antigen and pro-angiogenic molecules. BACKGROUND:...
Published: 6/27/2024   |   Inventor(s): Yvonne Chen
Keywords(s): Cancer, Cancer Immunotherapy, CAR-T cell therapy, immunosuppression, Immunosuppressive Drug, Immunotherapy, solid tumors, Tumor microenvironment, tumor vasculature, VEGF
Category(s): Therapeutics > Oncology
Targeting Serotonin Transporter (SERT) for Cancer Immunotherapy (UCLA Case No. 2024-204)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have unveiled a novel therapeutic strategy utilizing SSRIs for solid cancer immunotherapy. BACKGROUND: Immunotherapy has become a highly effective method to combat cancer that enhances a patient’s immune system to attack tumors with high specificity. For instance,...
Published: 6/18/2024   |   Inventor(s): Lili Yang
Keywords(s): Cancer, Immune checkpoint blockade, immune checkpoint inhibitors, Immunotherapy, selective serotonin reuptake inhibitors (SSRIs), serotonin, solid tumors, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Human Glioblastoma Model (UCLA Case No. 2023-273/2024-151)
UCLA researchers in the Department of Biological Chemistry have developed a novel method to study glioblastoma using human brain organoids. BACKGROUND: The National Institutes of Health defines glioblastoma as the most malignant and pervasive subtype of glioma, or glial-based cancer, and report that it is the most common primary brain tumor in adults....
Published: 6/18/2024   |   Inventor(s): Aparna Bhaduri
Keywords(s): Brain cancer, Brain organoid, Brain Tumor, Cancer, Glioblastoma, Organoids
Category(s): Therapeutics > CNS and Neurology, Therapeutics > Oncology
Synthetic Lethality of IR with ABBV-155 in Glioblastoma (GBM) (UCLA Case No. 2021-232)
UCLA researchers in the Department of Molecular and Medical Pharmacology have discovered that irradiation therapy can be combined with an antibody drug conjugate to form a novel therapeutic strategy to treat and extend survival of glioblastoma patients. BACKGROUND: Glioblastoma (GBM) is a fast-growing and aggressive brain tumor. The National Brain...
Published: 8/28/2024   |   Inventor(s): David Nathanson
Keywords(s): Antibody-Drug Conjugate, Apoptosis, Brain cancer, Cancer, Glioblastoma, irradiation
Category(s): Therapeutics > Oncology
Inhibitory Chimeric Antigen Receptors That Reduce Car-T Cell “On-Target, Off-Tumor” Toxicity (UCLA Case No. 2022-186)
­SUMMARY: UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics, and the Department of Molecular and Medical Pharmacology have recently developed a novel approach which improves the kinetics and specificity of CAR T-cell therapy. BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy makes use of reengineered...
Published: 5/16/2024   |   Inventor(s): Owen Witte
Keywords(s): blood cancers, CAR-T cell therapy
Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics
Strategies to Detect, Prevent and Reverse Acquired Resistance to Immune Checkpoint Blockade Therapy (UCLA Case No. 2024-085)
UCLA researchers in the Department of Medicine have uncovered novel mechanism of acquired resistance against immune checkpoint blockade therapy in melanoma patients. BACKGROUND: Immune checkpoint blockade (ICB) therapy is a type of cancer immunotherapy that targets immune system components in order to reactivate immune cells to combat tumor cells....
Published: 5/8/2024   |   Inventor(s): Roger Lo
Keywords(s): acquired resistance, Apoptosis, Cancer, Cancer Immunotherapy, Immune checkpoint blockade, Immunotherapy, Melanoma, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
1 2 3 4 5 6 7 8 9 10 ...